MBX Biosciences, Inc. (MBX)
NASDAQ:MBX
Top Page
MBX Biosciences, Inc.
(NASDAQ:MBX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$32.00
▲(2.24% Upside)
Action:ReiteratedDate:03/13/26
The score is supported primarily by strong capitalization and positive clinical/regulatory momentum (Phase 3 planning and orphan designations), but it is held back by pre-revenue status with widening losses and rising cash burn, plus weak technicals with the stock trading below key moving averages.
Positive Factors
Balance sheet strength
Very low leverage and a materially larger equity base provide durable financial flexibility to fund multi-year R&D programs without immediate solvency pressure. This lowers refinancing risk, supports hiring and capex, and gives management time to advance trials toward value-accretive inflection points.
Negative Factors
Pre-revenue status
Being pre-revenue means commercial validation is pending; the company must rely on successful trial outcomes and future launches to generate consistent cash flow. This structural gap increases financing dependency and elongates time to sustainable profitability and positive returns for shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and a materially larger equity base provide durable financial flexibility to fund multi-year R&D programs without immediate solvency pressure. This lowers refinancing risk, supports hiring and capex, and gives management time to advance trials toward value-accretive inflection points.
Read all positive factors
MBX Biosciences, Inc. (MBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.50B
Dividend YieldN/A
Average Volume (3M)543.23K
Price to Earnings (P/E)―
Beta (1Y)2.10
Revenue GrowthN/A
EPS Growth-44.79%
CountryUS
Employees43
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding47,510,242
10 Day Avg. Volume457,253
30 Day Avg. Volume543,226
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio-14.06
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.43K
Enterprise Value/Ebitda-10.78
Forecast
1Y Price Target
$66.00Price Target Upside110.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.83
Revenue Forecast (FY)N/A
MBX Biosciences, Inc. Business Overview & Revenue Model
Company Description
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroi...
How the Company Makes Money
null...
MBX Biosciences, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
25
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -248.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -98.06M | -67.95M | -35.15M | -25.70M |
| Net Income | -86.97M | -61.92M | -32.56M | -26.14M |
Balance Sheet | ||||
| Total Assets | 385.14M | 268.54M | 84.18M | 45.09M |
| Cash, Cash Equivalents and Short-Term Investments | 373.70M | 262.15M | 80.68M | 42.46M |
| Total Debt | 596.00K | 171.00K | 324.00K | 461.00K |
| Total Liabilities | 15.92M | 11.09M | 156.65M | 87.70M |
| Stockholders Equity | 369.22M | 257.44M | -72.47M | -42.60M |
Cash Flow | ||||
| Free Cash Flow | -81.88M | -55.55M | -32.11M | -23.56M |
| Operating Cash Flow | -79.95M | -54.68M | -31.98M | -23.12M |
| Investing Cash Flow | -83.70M | -160.59M | -30.93M | -11.41M |
| Financing Cash Flow | 189.59M | 234.10M | 69.22M | 46.06M |
MBX Biosciences, Inc. Risk Analysis
MBX Biosciences, Inc. disclosed 93 risk factors in its most recent earnings report. MBX Biosciences, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
MBX Biosciences, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $6.08B | -39.12 | -20.02% | ― | ― | 12.45% | |
55 Neutral | $2.00B | -13.06 | -34.75% | ― | ― | -17.01% | |
54 Neutral | $1.50B | -13.24 | -28.72% | ― | ― | -44.79% | |
54 Neutral | $987.06M | -37.98 | -444.41% | ― | ― | -13.14% | |
53 Neutral | $1.60B | -5.54 | -64.21% | ― | 48.32% | -1.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
39 Underperform | $81.53M | -3.72 | 264.70% | ― | -58.17% | -116.24% |
* Healthcare Sector Average
MBX
MBX Biosciences, Inc.
31.66
25.39
404.94%
KALV
KalVista Pharmaceuticals
19.27
8.73
82.83%
GOSS
Gossamer Bio
0.35
-0.43
-55.34%
NRIX
Nurix Therapeutics
15.60
6.79
77.07%
TERN
Terns Pharmaceuticals
52.66
50.52
2360.75%
TYRA
Tyra Bioscience
37.13
29.58
391.79%
MBX Biosciences, Inc. Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
MBX Biosciences Advances Canvuparatide After Phase 2 FDA Meeting
Positive
Mar 9, 2026
On March 9, 2026, MBX Biosciences reported that it had successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration on its once-weekly parathyroid hormone prodrug canvuparatide for chronic hypoparathyroidism. The FDA...
Business Operations and StrategyExecutive/Board Changes
MBX Biosciences Announces CFO Transition and Interim Appointment
Positive
Feb 27, 2026
On February 24, 2026, MBX Biosciences, Inc. signed a lease with 5 Burlington Woods, LLC for about 13,642 square feet of new office and lab space in Burlington, Mass., with a four-year term beginning five months after an expected May 1, 2026 commen...
Business Operations and StrategyPrivate Placements and Financing
MBX Biosciences Raises $87 Million in ATM Offering
Positive
Feb 5, 2026
On February 4, 2026, MBX Biosciences, Inc. closed the sale of 2,250,986 shares of its common stock through its at-the-market offering program at a volume-weighted average price of $38.76 per share, raising approximately $87.1 million in gross proc...
Business Operations and StrategyExecutive/Board Changes
MBX Biosciences Appoints Laurie Stelzer to Board, Audit Chair
Positive
Jan 22, 2026
On January 20, 2026, MBX Biosciences expanded its board of directors to eight members and appointed experienced biopharmaceutical finance executive Laurie Stelzer as an independent Class I director, to serve until the company’s 2028 annual m...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
MBX Biosciences Highlights 2026 Outlook and Pipeline Progress
Positive
Jan 12, 2026
On January 11, 2026, MBX Biosciences announced it would present a 2026 outlook and business update at the 44th Annual J.P. Morgan Healthcare Conference, highlighting a strong pipeline of endocrine and metabolic programs and a solid balance sheet. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.